Sarepta Therapeutics stock jumped in early trading, climbing approximately 6.1% after the company announced that the U.S. Food and Drug Administration has accepted for filing supplemental New Drug Applications for AMONDYS 45 (casimersen) and VYONDYS 53 (golodirsen). The FDA has assigned a Prescription Drug User Fee Act target action date of February 28, 2027 for the reviews, a milestone that moves the therapies closer to potential conversion from accelerated to full traditional approval.
The sNDA submissions rely in part on data from the Phase 3 ESSENCE confirmatory trial. That study did not meet statistical significance on its primary endpoint but did show numerical trends in favor of the treatment arms. Sarepta has also provided post-hoc analyses intended to add further context to the observed benefit profile.
Market participants responded positively to the regulatory development. Adding to the favorable tone, Mizuho reiterated its Outperform rating on Sarepta and kept a $31.00 price target, explicitly citing the FDA acceptance as a constructive regulatory event. The analyst community remains split on the company’s outlook - for example, Barclays had maintained a Hold rating as recently as June 18 - but Mizuho’s reaffirmation supplied a timely bullish counterweight that helped amplify investor enthusiasm.
The move in SRPT shares took place against a supportive equity market backdrop. During the session, the NASDAQ rose roughly 1.0% and the S&P 500 gained about 0.5%, conditions that generally favor gains in biotech names. Sarepta’s PMO franchise, which remains the company’s principal revenue driver, recorded $228.6 million in net product revenues in the first quarter of 2026.
Investors appeared to interpret the FDA acceptance as a concrete near-term regulatory catalyst that could reduce a key overhang on the stock if traditional approvals are secured. SRPT reached a session high of $18.08, a level well above its 52-week low of $10.42, though still below its 52-week peak of $25.32.
Context and implications
The FDA acceptance signals that the agency found the submissions sufficiently complete to begin formal review. That procedural step establishes the PDUFA timetable and sets the stage for a substantive evaluation of the ESSENCE data package and supporting analyses. For investors, the acceptance provides a defined regulatory milestone to monitor ahead of the February 28, 2027 action date.
Market reaction drivers
- Regulatory progress tied directly to potential conversion from accelerated to traditional approvals for two exon-skipping therapies.
- An analyst reaffirmation from Mizuho citing the acceptance as constructive, which helped offset divergent opinions among other analysts.
- A broadly positive market session that favored biotech equities during the trading day.
What remains uncertain
- The Phase 3 ESSENCE study did not achieve statistical significance on its primary endpoint; interpretation of numerical trends and post-hoc analyses will be central to the FDA review.
- Final regulatory outcomes remain unresolved until the agency completes its review and issues a decision by the PDUFA target date.
- Analyst coverage and market sentiment are mixed, and differing viewpoints could continue to influence share price volatility.